Vyome Holdings, Inc.
HIND
NASDAQ·Healthcare·Biotechnology·Mkt cap $15.6M
$2.22
▼ -0.45%
P/E
—
Mkt Cap
$15.6M
52-Wk Range
$1.75–$9.56
52-Week Range
$1.75 - $9.56
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 72.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized focus on underserved immuno-inflammatory and rare disease markets
- Clinical-stage pipeline with multiple development programs
- Strategic geographic presence enabling global market access
- Experienced biotechnology research and development team
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Strong growth ahead
Advancement of clinical trials and regulatory approvals
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+1.4% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying HIND right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 12, 2026
Reported EPS of -$0.10 vs -$0.19 consensus (+47.4% surprise). Revenue of $27.0K vs $27.0K expected (0.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+47.4%
Revenue trend · last 8Q
—
—
-43%
-37%
-98%
-98%
-97%
-98%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.3M
$1.8M
$1.1M
$1.2M
$34.6K
$36.6K
$31.6K
$27.0K
Margins · last 8Q
Gross
43.3%
Operating
—
Profit
-2543.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How HIND stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related